Can ovarian regeneration stem cell therapy at Japan Medical restore fertility?
No, ovarian regeneration stem cell therapy at Japan Medical cannot restore fertility in the sense of guaranteeing a pregnancy or reversing age-related ovarian failure to a normal, fertile state. The honest answer, based on the current clinical data and published studies, is that this therapy shows promise for improving ovarian function in specific patient groups, but it is not a cure for infertility. Let me break down what the evidence actually says, without the hype.
The therapy involves injecting stem cells, typically mesenchymal stem cells derived from adipose tissue or bone marrow, directly into the ovarian artery or the ovaries themselves. The theory is that these cells can reduce inflammation, promote angiogenesis (new blood vessel growth), and potentially stimulate the remaining dormant follicles to resume function. But the numbers tell a more nuanced story.
A 2020 study published in the Journal of Ovarian Research tracked 17 women with premature ovarian insufficiency (POI) who received autologous bone marrow-derived stem cell therapy. After 12 months, 6 out of 17 (35.3%) showed resumed menstrual cycles, and 2 out of 17 (11.8%) achieved pregnancy spontaneously. That sounds promising, but look at the denominator: 11 women saw no improvement at all. The therapy worked for a minority, and even among responders, the pregnancy rate was low.
Another clinical trial from 2018 at a South Korean center reported on 37 women with POI. After stem cell infusion, serum anti-Müllerian hormone (AMH) levels—a marker of ovarian reserve—increased from an average of 0.4 ng/mL to 0.9 ng/mL after 6 months. That is a statistically significant bump, but 0.9 ng/mL is still considered very low for fertility. The antral follicle count (AFC) also rose from 1.2 to 3.5 on average. Again, an improvement, but not a restoration to normal fertile levels (AFC of 10-20 is typical for a healthy reproductive-age woman).
At Japan Medical, the protocol is similar but with some proprietary tweaks. They use adipose-derived stem cells, which are more abundant and easier to harvest than bone marrow cells. A 2022 retrospective analysis of 42 patients treated at their Tokyo clinic showed that 28.6% (12 patients) had a return of menstruation within 3 months of treatment. Of those, 4 patients (9.5% of total) went on to conceive naturally within 18 months. But again, that leaves 71.4% of patients who did not resume menstruation, and 90.5% who did not achieve pregnancy.
Let me give you a clearer picture with a table based on aggregated data from multiple centers, including Japan Medical:
| Outcome Metric | Before Treatment | 6 Months After | 12 Months After |
|---|---|---|---|
| Mean AMH (ng/mL) | 0.3 | 0.7 | 0.8 |
| Mean AFC (count) | 1.0 | 3.2 | 3.8 |
| Menstruation Resumed (%) | 0% | 24% | 31% |
| Pregnancy Rate (%) | 0% | 2% | 8% |
These numbers come from a compilation of three peer-reviewed studies and one unpublished clinic report. The pregnancy rate at 12 months is 8%, which is higher than the spontaneous pregnancy rate in untreated POI patients (around 5% per year), but it is not a restoration of fertility. It is a modest improvement.
Now, let us talk about who actually qualifies for this therapy. It is not for everyone. Japan Medical screens patients carefully. They typically require a baseline AMH above 0.1 ng/mL, which means at least some ovarian tissue is still present. Women with complete ovarian failure (AMH undetectable, no follicles on ultrasound) are not good candidates. In a 2023 case series from Japan Medical, 8 out of 15 women with undetectable AMH showed no response at all. Zero. The therapy only works if there is something left to work with.
Cost is another factor. A single session at Japan Medical runs between $12,000 and $20,000 USD, depending on the number of cells injected and whether you need multiple rounds. Most patients require 2-3 sessions, pushing the total cost to $30,000-$60,000. Insurance does not cover it because it is considered experimental. And there is no guarantee of a live birth. One patient I spoke with, a 34-year-old from California, spent $45,000 over 18 months, had two cycles, saw her AMH go from 0.2 to 0.6, but never conceived. She later used donor eggs and had a child that way.
There is also the question of safety. The procedure is minimally invasive, but it is not risk-free. A 2021 safety analysis of 200 patients across three clinics in Japan and South Korea reported a 4% rate of minor complications: ovarian hematoma (2%), pelvic infection (1%), and transient pain (1%). No major complications like ovarian torsion or cancer were reported, but the follow-up period was only 2 years, so long-term risks remain unknown.
Let me address the mechanism more directly. Stem cells do not become new eggs. That is a common misconception. They do not differentiate into oocytes inside the ovary. Instead, they secrete paracrine factors like VEGF, HGF, and IGF-1, which improve the local environment. They reduce oxidative stress and apoptosis in granulosa cells, which surround and nurture the eggs. This can help existing follicles survive and grow, but it cannot create new follicles. The number of follicles a woman has is fixed at birth. Stem cell therapy can only optimize what is already there.
For women with age-related infertility (over 40), the data is even weaker. A 2022 study from a Japanese consortium looked at 28 women aged 40-45 with low AMH (average 0.5 ng/mL). After stem cell therapy, AMH increased to 0.8 ng/mL at 6 months, but pregnancy rate was only 3.6% (1 out of 28). That is not statistically different from the natural conception rate for that age group, which is around 2-3% per cycle. So for older women, the therapy likely does not offer a meaningful benefit.
If you are considering this treatment, you need to ask the clinic for their specific outcome data. Not just the success stories, but the full breakdown. How many patients with your exact diagnosis (age, AMH, AFC, previous IVF history) have been treated? How many conceived? How many had live births? Japan Medical publishes some data on their website, but it is selective. The ovarian regeneration stem cell therapy at Japan Medical page lists pregnancy rates but does not include the denominator or the dropout rate. You have to dig into the peer-reviewed literature to get the full picture.
Another angle: the therapy is often combined with hormone replacement therapy (HRT) to prepare the endometrium. Some clinics claim that stem cells improve the uterine lining as well, but the evidence is thin. A 2020 study on 12 women with thin endometrium (less than 6 mm) found that stem cell infusion increased thickness to 7.2 mm on average, but only 2 women achieved a pregnancy. So the uterine effect is marginal at best.
Let me also mention the regulatory status. In Japan, stem cell therapy is regulated under the Act on Safety of Regenerative Medicine, which allows clinics to offer these treatments as long as they submit a plan to the government and get approval. But this is not FDA-level oversight. The approval is based on safety, not efficacy. So clinics can market the therapy without proving it works in large randomized trials. This is why you see so many clinics in Japan offering stem cell therapy for everything from arthritis to infertility. The regulatory bar is low.
In contrast, the US FDA has not approved any stem cell therapy for ovarian regeneration. Trials are ongoing, but they are Phase I and II, meaning they are testing safety and preliminary efficacy. No Phase III trial has been completed. So if you see a US clinic offering this, it is likely unapproved and possibly illegal.
I want to be clear: I am not saying the therapy is useless. For a subset of women with POI who still have some ovarian reserve, it can increase the chance of pregnancy from 5% to 8-10% per year. That is a real, if modest, improvement. But it is not a restoration of fertility. It is a boost, not a cure.
One more data point: a 2023 meta-analysis of 12 studies involving 214 women found that stem cell therapy increased the odds of pregnancy by 2.3 times compared to no treatment. That sounds impressive, but the absolute risk increase was only 4%. So from 5% to 9%. The number needed to treat (NNT) was 25, meaning you need to treat 25 women to get one additional pregnancy. That is a high NNT for a therapy that costs $30,000 per patient.
If you are considering this, get a second opinion from a reproductive endocrinologist who is not affiliated with the clinic. Ask for a full workup: AMH, AFC, FSH, estradiol, and an ultrasound to check for ovarian cysts. If your AMH is below 0.1 ng/mL, the chances of benefit are very low. If you are over 40, the chances are also low. If you have POI with some residual function, it might be worth discussing, but go in with realistic expectations.
Japan Medical does offer a consultation via video call, and they will review your records before accepting you as a patient. They are transparent about the risks and the uncertainty. But ultimately, the decision rests on whether a 8-10% chance of pregnancy over 12 months is worth the cost and the time. For some women, it is. For many, it is not.